Marc S Sabatine

List of Publications by Year
in descending order

461	80,413	668 122	460 272
papers	citations	h-index	g-index

501	501	501	47847
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
2	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	27.0	4,179
3	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	27.0	4,159
4	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
5	2014 AHA/ACC Guideline for theÂManagement of Patients WithÂNonâ€“ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 64, e139-e228.	2.8	2,746
6	Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine, 2009, 360, 354-362.	27.0	2,209
7	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	13.7	1,958
8	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.8	1,753
9	Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine, 2005, 352, 1179-1189.	27.0	1,739
10	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
11	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1500-1509.	27.0	1,352
12	2016 ACC/AHA Guideline FocusedÂUpdate on Duration of DualÂAntiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 1082-1115.	2.8	1,232
13	The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2001, 345, 1014-1021.	27.0	1,217
14	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. JAMA - Journal of the American Medical Association, 2011, 305, 2556.	7.4	1,197
15	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. Circulation, 2016, 134, e123-55	1.6	1,069
16	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. JAMA - Journal of the American Medical Association, 2010, 304, 1821.	7.4	980
17	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289.	7.4	974
18	2014 AHA/ACC Guideline for the Management of Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation, 2014, 130, 2354-2394.	1.6	938

#	Article	IF	Citations
19	2014 AHA/ACC Guideline for the Management of Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes. Circulation, 2014, 130, e344-426.	1.6	928
20	Myocardial infarction accelerates atherosclerosis. Nature, 2012, 487, 325-329.	27.8	874
21	A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease. New England Journal of Medicine, 2009, 361, 2538-2547.	27.0	786
22	Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes. Circulation, 2002, 105, 1760-1763.	1.6	680
23	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, The, 2009, 374, 989-997.	13.7	650
24	Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 294, 1224.	7.4	644
25	Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel. Circulation, 2009, 119, 2553-2560.	1.6	615
26	Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes. Circulation, 2005, 111, 2042-2049.	1.6	613
27	Variation inPCSK9andHMGCRand Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine, 2016, 375, 2144-2153.	27.0	596
28	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet, The, 2015, 385, 2264-2271.	13.7	564
29	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation, 2018, 137, 338-350.	1.6	559
30	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITONâ€“TIMI 38 trial: a pharmacogenetic analysis. Lancet, The, 2010, 376, 1312-1319.	13.7	551
31	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
32	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
33	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, The, 2017, 390, 1962-1971.	13.7	487
34	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLAREâ€“TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	11.4	482
35	Association of Triglyceride-Lowering LPL Variants and LDL-Câ€“Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	7.4	460
36	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 941-950.	11.4	452

#	Article	IF	Citations
37	Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia. Circulation, 2005, 112, 3868-3875.	1.6	443
38	2014 AHA/ACC Guideline for theÂManagement of Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes: Executive Summary. Journal of the American College of Cardiology, 2014, 64, 2645-2687.	2.8	424
39	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
40	Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation, 2003, 107, 690-695.	1.6	412
41	Early Invasive vs Conservative Treatment Strategies in Women and Men With Unstable Angina and Nonâ€“ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2008, 300, 71.	7.4	401
42	Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Nonâ€“ST-elevation myocardial infarction. Journal of the American College of Cardiology, 2003, 41, 1264-1272.	2.8	393
43	Prevalence and Determinants of Troponin T Elevation in the General Population. Circulation, 2006, 113, 1958-1965.	1.6	383
44	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, The, 2012, 380, 2007-2017.	13.7	379
45	Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction. Circulation, 2004, 109, 2186-2190.	1.6	378
46	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 633-643.	27.0	366
47	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
48	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
49	Metabolic Signatures of Exercise in Human Plasma. Science Translational Medicine, 2010, 2, 33ra37.	12.4	337
50	Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. Journal of the American College of Cardiology, 2004, 44, 1988-1995.	2.8	320
51	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. Circulation, 2007, 115, 1528-1536.	1.6	316
52	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	2.8	316
53	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2011, 306, 2221-8.	7.4	313
54	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728.	2.8	303

#	Article	IF	Citations
55	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443.	2.2	293
56	Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction. Circulation, 2008, 117, 1936-1944.	1.6	290
57	Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial. Circulation, 2006, 114, 281-288.	1.6	284
58	Prognostic Value of Cardiac Troponin I Measured With a Highly Sensitive Assay in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 61, 1240-1249.	2.8	271
59	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	7.1	264
60	Quantification of Cardiovascular Biomarkers in Patient Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution. Molecular and Cellular Proteomics, 2009, 8, 2339-2349.	3.8	263
61	Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2002, 40, 1761-1768.	2.8	250
62	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1243-1275.	0.8	249
63	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2017, 318, 947.	7.4	247
64	Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. Journal of Clinical Investigation, 2008, 118, 3503-3512.	8.2	244
65	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 141, 90-99.	1.6	244
66	Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry. Clinical Chemistry, 2009, 55, 1108-1117.	3.2	243
67	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241
68	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. American Journal of Human Genetics, 2012, 90, 410-425.	6.2	239
69	Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. European Heart Journal, 2008, 30, 162-169.	2.2	233
70	A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nature Biotechnology, 2011, 29, 635-643.	17.5	229
71	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	1.6	224
72	Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 205-214.	2.8	210

#	Article	IF	Citations
73	Lipoprotein-Associated Phospholipase A ₂ and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Circulation, 2006, 113, 1745-1752.	1.6	209
74	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	27.0	205
75	Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation, 2014, 129, 234-243.	1.6	204
76	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2Â°P-TIMI 50 trial. Lancet, The, 2012, 380, 1317-1324.	13.7	202
77	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation, 2018, 138, 756-766.	1.6	200
78	Detection of High-Risk Atherosclerotic Plaque. JACC: Cardiovascular Imaging, 2012, 5, 941-955.	5.3	198
79	B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 335-339.	2.8	196
80	PCSK9 inhibitors: clinical evidence and implementation. Nature Reviews Cardiology, 2019, 16, 155-165.	13.7	195
81	Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2005, 294, 2866.	7.4	194
82	Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation, 2018, 138, 131-140.	1.6	194
83	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
84	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2016, 315, 1591.	7.4	190
85	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research, 2016, 57, 1086-1096.	4.2	180
86	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUSâ€“TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	2.8	179
87	Iatrogenic aortic dissection. American Journal of Cardiology, 2002, 89, 623-626.	1.6	177
88	Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet, The, 2014, 384, 599-606.	13.7	172
89	Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation, 2016, 134, 270-285.	1.6	172
90	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes. Circulation, 2019, 140, 1308-1317.	1.6	172

#	Article	IF	Citations
91	Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective Trials. Journal of the American College of Cardiology, 2008, 51, 435-443.	2.8	171
92	Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Nonâ€“ST-Elevation Myocardial Infarction. Circulation, 2004, 109, 580-586.	1.6	169
93	Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. Circulation, 2006, 114, 550-557.	1.6	168
94	Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. European Heart Journal, 2008, 29, 1096-1102.	2.2	168
95	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	13.7	167
96	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
97	Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial. Circulation, 2006, 114, 26-31.	1.6	162
98	AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy. Circulation, 2013, 128, 962-969.	1.6	161
99	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	7.1	159
100	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal, 2016, 173, 94-101.	2.7	158
101	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. JAMA Cardiology, 2018, 3, 823.	6.1	158
102	Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE ITâ€“TIMI 22 Study. Journal of the American College of Cardiology, 2006, 47, 2326-2331.	2.8	157
103	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. Journal of the American College of Cardiology, 2015, 65, 2638-2651.	2.8	156
104	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2280-2287.	13.7	153
105	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	2.8	152
106	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	28.9	152
107	Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. American Heart Journal, 2008, 155, 49-55.	2.7	151
108	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	2.2	151

#	Article	IF	Citations
109	Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. Journal of the American College of Cardiology, 2008, 51, 449-455.	2.8	146
110	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
111	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	7.4	144
112	Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 50, 2117-2124.	2.8	143
113	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation, 2016, 134, 304-313.	1.6	143
114	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. Circulation, 2020, 141, 616-623.	1.6	143
115	Role of ST2 in Nonâ€“ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clinical Chemistry, 2012, 58, 257-266.	3.2	140
116	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 203-210.	2.4	138
117	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y₁₂inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 2016, 37, 1133-1142.	2.2	138
118	Long-term Low-Density Lipoprotein Cholesterolâ€“Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. JAMA Cardiology, 2017, 2, 598.	6.1	137
119	Myocardial Ischemia Induced by Rapid Atrial Pacing Causes Troponin T Release Detectable by a Highly Sensitive Assay. Journal of the American College of Cardiology, 2011, 57, 2398-2405.	2.8	129
120	Diagnostic and Prognostic Utility of Brain Natriuretic Peptide in Subjects Admitted to the ICU With Hypoxic Respiratory Failure Due to Noncardiogenic and Cardiogenic Pulmonary Edema. Chest, 2007, 131, 964-971.	0.8	128
121	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128
122	Long-Term Prognostic Value of Neopterin. Circulation, 2007, 115, 3071-3078.	1.6	125
123	Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease. Circulation, 2012, 125, 233-240.	1.6	125
124	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738.	2.2	125
125	Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet, The, 2009, 374, 787-795.	13.7	123
126	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 2011, 88, 6-18.	6.2	122

#	Article	IF	Citations
127	Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I. Journal of the American College of Cardiology, 2010, 55, 2118-2124.	2.8	120
128	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 499.	6.1	120
129	The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology, 2009, 54, 1935-1945.	2.8	119
130	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1069.	6.1	119
131	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€“TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	2.7	117
132	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.8	115
133	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal, 2014, 35, 2249-2259.	2.2	115
134	Efficacy and Safety of Evolocumab inÂChronic Kidney Disease in the FOURIERÂTrial. Journal of the American College of Cardiology, 2019, 73, 2961-2970.	2.8	115
135	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet, The, 2021, 398, 2247-2257.	13.7	115
136	Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel. Journal of the American College of Cardiology, 2009, 53, 1273-1278.	2.8	113
137	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes and Endocrinology,the, 2019, 7, 899-911.	11.4	111
138	Prognostic Utility of Lipoprotein-Associated Phospholipase A ₂ for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2463-2469.	2.4	110
139	The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention. Journal of the American College of Cardiology, 2009, 54, 678-685.	2.8	109
140	Platelet Inhibition With Ticagrelor 60ÂmgÂVersus 90 mg Twice Daily in theÂPEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	2.8	108
141	Association of Apolipoprotein Bâ€“Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology, 2022, 7, 250.	6.1	108
142	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology, 2018, 3, 749.	6.1	105
143	Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of the American College of Cardiology, 2009, 54, 2290-2295.	2.8	103
144	Vitamin D Therapy in Individuals With Prehypertension or Hypertension. Circulation, 2015, 131, 254-262.	1.6	103

#	Article	IF	Citations
145	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke, 2020, 51, 1546-1554.	2.0	102
146	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 2132-2146.	2.8	101
147	Inflammatory Biomarkers in Acute Coronary Syndromes. Circulation, 2006, 113, e72-5.	1.6	100
148	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	100
149	The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y ₁₂ Inhibitor in Patients After Percutaneous Coronary Intervention. Circulation, 2020, 142, 538-545.	1.6	98
150	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
151	<scp>DECLAREâ€TIMI</scp> 58: Participantsâ€™ baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	4.4	96
152	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. American Heart Journal, 2016, 175, 193-201.e3.	2.7	95
153	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. European Heart Journal, 2019, 40, 2775-2781.	2.2	95
154	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 1569-1577.	1.6	94
155	An Invasive or Conservative Strategy in Patients With Diabetes Mellitus and Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 60, 106-111.	2.8	91
156	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	2.2	90
157	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirinâ€“Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	2.7	89
158	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. JAMA Cardiology, 2017, 2, 1385.	6.1	89
159	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 2016, 1, 425.	6.1	88
160	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	4.1	87
161	Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: Observations from the PROTECT-TIMI 30 Trial. American Heart Journal, 2009, 158, 386-391.	2.7	86
162	Prognostic Performance of Multiple Biomarkers in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 1644-1653.	2.8	86

#	Article	IF	Citations
163	Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 63, 2421-2428.	2.8	84
164	Identification of Genetic Variants Associated With Response to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1310-1315.	2.4	83
165	Effect of Vupanorsen on Nonâ€“High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation, 2022, 145, 1377-1386.	1.6	81
166	Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. European Heart Journal, 2011, 32, 697-705.	2.2	77
167	Inflammatory Biomarkers in Acute Coronary Syndromes. Circulation, 2006, 113, e152-5.	1.6	75
168	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	4.1	75
169	Prognostic Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients with Nonâ€“ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2014, 60, 158-164.	3.2	74
170	Efficacy and Safety of Ticagrelor OverÂTime in Patients With Prior MI inÂPEGASUS-TIMI 54. Journal of the American College of Cardiology, 2017, 70, 1368-1375.	2.8	74
171	Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L16-L22.	2.9	73
172	B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 55, 1189-1196.	2.8	73
173	A Missense Variant in PLEC Increases RiskÂof Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2157-2168.	2.8	73
174	Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk score for unstable angina pectoris and nonâ€“ST-elevation myocardial infarction in the TIMI III registry. American Journal of Cardiology, 2002, 90, 303-305.	1.6	72
175	Evaluation of the Paraoxonases as Candidate Genes for Stroke. Stroke, 2005, 36, 2346-2350.	2.0	72
176	Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 1800-1807.	3.2	72
177	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€“TIMI 58 Study. Diabetes Care, 2020, 43, 468-475.	8.6	72
178	The Search for a Biomarker of Cardiac Ischemia. Clinical Chemistry, 2003, 49, 537-539.	3.2	71
179	Variability of Individual Platelet ReactivityÂOver Time in Patients TreatedÂWith Clopidogrel. Journal of the American College of Cardiology, 2014, 64, 361-368.	2.8	70
180	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, 2016, 37, ehv482.	2.2	70

#	Article	IF	Citations
181	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	13.7	70
182	The thrombolysis in myocardial infarction risk score in unstable angina/nonâ€“ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2003, 41, S89-S95.	2.8	66
183	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. JAMA Cardiology, 2019, 4, 613.	6.1	66
184	Implications of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Nonâ€“ST-Elevation Myocardial Infarction. Circulation, 2004, 109, 874-880.	1.6	65
185	Platelet Biology and Response to Antiplatelet Therapy in Women. Journal of the American College of Cardiology, 2012, 59, 891-900.	2.8	65
186	Association of Blood Glucose With Angiographic and Clinical Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction (from the CLARITY-TIMI-28 Study). American Journal of Cardiology, 2008, 101, 303-307.	1.6	64
187	Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation, 2005, 112, 3846-3854.	1.6	63
188	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	6.1	63
189	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 373, 1271-1275.	27.0	62
190	Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 2020, 75, 2283-2293.	2.8	62
191	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 2020, 141, 1600-1607.	1.6	61
192	The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2006, 48, 37-42.	2.8	60
193	Correlation between the TIMI risk score and high-risk angiographic findings in nonâ€“ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal, 2005, 149, 846-850.	2.7	59
194	Anticoagulation With Otamixaban and Ischemic Events in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2013, 310, 1145.	7.4	58
195	LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. European Journal of Preventive Cardiology, 2021, 28, 805-812.	1.8	57
196	Effect of dapagliflozin on anaemia in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2021, 23, 617-628.	7.1	57
197	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients WithÂMultivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496.	2.8	56
198	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	6.1	56

#	Article	IF	Citations
199	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, 820-830.	3.9	56
200	Influence of Race on Death and Ischemic Complications in Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes Despite Modern, Protocol-Guided Treatment. Circulation, 2005, 111, 1217-1224.	1.6	55
201	Prospective Evaluation of Pregnancy-Associated Plasma Protein-A and Outcomes in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 60, 332-338.	2.8	55
202	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clinical Chemistry, 2009, 55, 265-273.	3.2	54
203	Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, doubleâ€blind, placeboâ€controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidâ€lowering therapyâ€”A cognitive study of patients enrolled in the <scp>FOURIER</scp> trial. Clinical Cardiology, 2017, 40, 59-65.	1.8	54
204	Outcomes of Women Compared With Men After Nonâ€“ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.	2.8	54
205	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
206	The prognostic value of serum myoglobin in patients with nonâ€“ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 2002, 40, 238-244.	2.8	52
207	Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes. Clinical Chemistry, 2003, 49, 1396-1398.	3.2	51
208	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapyâ€“Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. American Heart Journal, 2005, 149, 227-233.	2.7	51
209	Potent P2Y 12 Inhibitors in MenÂVersusÂWomen. Journal of the American College of Cardiology, 2017, 69, 1549-1559.	2.8	51
210	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
211	Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China. JAMA Network Open, 2020, 3, e2021677.	5.9	51
212	AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Programâ€“Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients. Journal of the American College of Cardiology, 2014, 63, 430-433.	2.8	50
213	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. JAMA Cardiology, 2021, 6, 139.	6.1	50
214	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	8.6	50
215	Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. American Journal of Cardiology, 2004, 93, 1362-1367.	1.6	49
216	Sharing Data from Cardiovascular Clinical Trials â€” A Proposal. New England Journal of Medicine, 2016, 375, 407-409.	27.0	49

#	Article	IF	Citations
217	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	8.6	49
218	The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. American Journal of Medicine, 2000, 109, 224-237.	1.5	48
219	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. American Heart Journal, 2011, 162, 518-526.e5.	2.7	48
220	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trialâ€“Thrombolysis in Myocardial Infarction 22 (PROVE ITâ€“TIMI 22). American Heart Journal, 2011, 161, 1147-1155.e1.	2.7	46
221	Case 36-2007. New England Journal of Medicine, 2007, 357, 2167-2178.	27.0	45
222	Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. European Heart Journal, 2008, 29, 984-991.	2.2	45
223	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab. JAMA Cardiology, 2019, 4, 59.	6.1	45
224	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology, 2009, 54, 2261-2276.	2.8	44
225	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 2020, 142, 734-747.	1.6	44
226	Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Communications Biology, 2018, 1, 68.	4.4	42
227	Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Journal of Thrombosis and Thrombolysis, 2007, 24, 85-91.	2.1	41
228	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. Journal of the American Heart Association, 2015, 4, .	3.7	41
229	Klotho, fibroblast growth factorâ€23, and the reninâ€“angiotensin system â€” an analysis from the PEACE trial. European Journal of Heart Failure, 2019, 21, 462-470.	7.1	41
230	Inflammatory Biomarkers in Acute Coronary Syndromes. Circulation, 2006, 113, e382-5.	1.6	40
231	Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	40
232	Integration of Proteomic-Based Tools for Improved Biomarkers of Myocardial Injury. Clinical Chemistry, 2010, 56, 194-201.	3.2	40
233	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Circulation, 2016, 134, 861-871.	1.6	40
234	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology,the, 2022, 10, 24-34.	11.4	40

#	Article	IF	Citations
235	Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). American Heart Journal, 2022, 251, 61-69.	2.7	40
236	Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2763-2768.	2.4	39
237	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal, 2008, 155, 910-917.	2.7	38
238	Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 562-567.	2.4	38
239	Design and Rationale of the LAPLACEâ€TIMI 57 Trial: A Phase II, Doubleâ€Blind, Placeboâ€Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy. Clinical Cardiology, 2012, 35, 385-391.	1.8	37
240	Concomitant Administration of Clopidogrel With Statins or Calcium-Channel Blockers. JACC: Cardiovascular Interventions, 2013, 6, 1275-1281.	2.9	37
241	Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel. Journal of the American College of Cardiology, 2007, 49, 2256-2263.	2.8	36
242	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 2021, 23, 1662-1672.	7.1	36
243	Pulmonary Cholesterol Crystal Embolization. Chest, 1997, 112, 1687-1692.	0.8	35
244	Inflammatory Biomarkers in Acute Coronary Syndromes. Circulation, 2006, 113, e289-92.	1.6	35
245	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. American Journal of Gastroenterology, 2009, 104, 2903-2917.	0.4	35
246	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€“glucose coâ€transporter 2 inhibitor therapy in <scp>DECLAREâ€TIMI</scp> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	7.1	35
247	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
248	Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction. Circulation, 2009, 119, 1195-1202.	1.6	34
249	Effect of Pravastatin Therapy on Coronary Events in Carriers of the KIF6 719Arg Allele from the Cholesterol and Recurrent Events Trial. American Journal of Cardiology, 2010, 105, 1300-1305.	1.6	34
250	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart, 2012, 98, 786-791.	2.9	34
251	Impact of ADCY9 Genotype on Response to Anacetrapib. Circulation, 2019, 140, 891-898.	1.6	34
252	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 473.	6.1	33

#	Article	IF	Citations
253	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <scp>DAPAâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 601-613.	7.1	33
254	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 513-525.	7.1	33
255	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. Journal of Thrombosis and Thrombolysis, 2016, 41, 374-383.	2.1	32
256	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 2019, 139, 366-375.	1.6	32
257	Gut Microbiotaâ€Dependent Trimethylamine Nâ€oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2020, 9, e015331.	3.7	32
258	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
259	Refractory systemic hypertension following type B aortic dissection. American Journal of Cardiology, 2001, 88, 686-688.	1.6	31
260	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. American Heart Journal, 2015, 169, 622-630.e6.	2.7	31
261	Evolocumab in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 785-788.	27.0	31
262	Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. American Heart Journal, 2002, 143, 966-970.	2.7	29
263	Timing of Angiography and Outcomes in High-Risk Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction Managed Invasively. Circulation, 2017, 136, 1895-1907.	1.6	29
264	Efficacy and safety of sodiumâ€“glucose coâ€transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	7.1	29
265	Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the American College of Cardiology, 2020, 75, 289-300.	2.8	29
266	Population and Personalized Medicine in the Modern Era. JAMA - Journal of the American Medical Association, 2014, 312, 1969.	7.4	28
267	Modes and timing of death in 66â€‰252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820.	2.2	28
268	Cardiorenal outcomes with dapagliflozin by baseline glucoseâ€lowering agents: Post hoc analyses from <scp>DECLAREâ€TIMI</scp> 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	4.4	28
269	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLAREâ€“TIMI 58 trial. European Heart Journal, 2022, 43, 2958-2967.	2.2	28
270	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1066-1076.	7.1	28

#	Article	IF	Citations
271	Elevation in serum troponin I predicts the benefit of tirofiban. Journal of Thrombosis and Thrombolysis, 2001, 11, 211-215.	2.1	27
272	Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. Journal of Thrombosis and Thrombolysis, 2007, 23, 173-179.	2.1	27
273	Association of Impaired Thrombolysis In Myocardial Infarction Myocardial Perfusion Grade With Ventricular Tachycardia and Ventricular Fibrillation Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2008, 51, 546-551.	2.8	27
274	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	2.2	27
275	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology, 2020, 5, 1255.	6.1	27
276	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLAREâ€TIMI 58 study. Diabetes, Obesity and Metabolism, 2020, 22, 1357-1368.	4.4	26
277	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 678.	6.1	26
278	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	6.1	26
279	Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 195-202.	1.0	25
280	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206.	3.0	25
281	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 1095-1106.	2.8	25
282	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	8.6	25
283	A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. American Journal of Cardiology, 2001, 88, 488-492.	1.6	24
284	Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. American Journal of Cardiology, 2003, 91, 457-461.	1.6	24
285	PCSK9 inhibition in patients with hypercholesterolemia. Trends in Cardiovascular Medicine, 2015, 25, 567-574.	4.9	24
286	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Journal of the American College of Cardiology, 2021, 77, 259-267.	2.8	24
287	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2021, 23, 632-643.	7.1	24
288	Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nature Medicine, 2022, 28, 89-95.	30.7	24

#	Article	IF	Citations
289	Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated With Higher Platelet Counts in Patients With ST-Elevation Myocardial Infarction (Results from CLARITY-TIMI 28). American Journal of Cardiology, 2006, 98, 761-763.	1.6	23
290	Sudden Cardiac Death in Patients With Stable Coronary Artery Disease and Preserved Left Ventricular Systolic Function. American Journal of Cardiology, 2008, 101, 457-461.	1.6	23
291	Cost-Effectiveness of Long-TermÂTicagrelor in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 527-538.	2.8	23
292	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. JAMA Cardiology, 2020, 5, 787.	6.1	23
293	Thrombolysis In Myocardial InfarctionÂ(TIMI) Study Group. Journal of the American College of Cardiology, 2021, 77, 2822-2845.	2.8	23
294	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. European Heart Journal, 2021, 42, 4821-4829.	2.2	23
295	Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	22
296	Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and nonâ€“ST-elevation myocardial infarction. American Heart Journal, 2006, 151, 25-31.	2.7	22
297	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiology, 2017, 2, 556.	6.1	22
298	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
299	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
300	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
301	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 78, 1499-1507.	2.8	22
302	Validation of an Automated Safety Surveillance System with Prospective, Randomized Trial Data. Medical Decision Making, 2009, 29, 247-256.	2.4	21
303	Case 28-2010. New England Journal of Medicine, 2010, 363, 1164-1173.	27.0	21
304	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis, 2017, 117, 940-947.	3.4	21
305	Minimal ST-segment deviation: A simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. American Heart Journal, 2002, 144, 790-795.	2.7	21
306	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21

#	Article	IF	Citations
307	Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. American Heart Journal, 2009, 157, 517-524.	2.7	20
308	Genetic Regulation of Platelet Receptor Expression and Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2372-2384.	2.4	20
309	Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in nonâ€“ST-segment elevation acute coronary syndromes with a planned early invasive strategy. American Heart Journal, 2012, 164, 817-824.e13.	2.7	20
310	Relation Between Time of Symptom Onset of <scp>ST</scp>â€Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. Clinical Cardiology, 2013, 36, 222-227.	1.8	20
311	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 2020, 43, 2878-2881.	8.6	20
312	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	8.6	20
313	Relation Between Myocardial Infarct Size and Ventricular Tachyarrhythmia Among Patients With Preserved Left Ventricular Ejection Fraction Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2009, 104, 475-479.	1.6	19
314	Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Thrombosis and Haemostasis, 2016, 116, 69-77.	3.4	19
315	Opportunities and Challenges in Mendelian Randomization Studies to Guide Trial Design. JAMA Cardiology, 2018, 3, 967.	6.1	19
316	Cardiovascular Genomics. Circulation, 2006, 113, e450-5.	1.6	18
317	Thrombus Precursor Protein and Clinical Outcomes in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2008, 51, 2422-2429.	2.8	18
318	Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human Genetics, 2011, 129, 17-23.	3.8	18
319	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 1996-1997.	27.0	18
320	Plasma Omegaâ€3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLINâ€TIMI 36. Journal of the American Heart Association, 2021, 10, e017401.	3.7	18
321	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. European Journal of Preventive Cardiology, 2022, 29, 895-902.	1.8	18
322	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 145, 158-169.	1.6	18
323	Predicting a late positive serum troponin in initially troponin-negative patients with nonâ€“ST-elevation acute coronary syndrome: Clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. American Heart Journal, 2006, 151, 360-366.	2.7	17
324	Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. European Heart Journal, 2006, 27, 2040-2045.	2.2	17

#	Article	IF	Citations
325	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 431-440.	1.0	17
326	Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era. JAMA Cardiology, 2017, 2, 935.	6.1	17
327	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	3.7	17
328	Will Diabetes Save the Platelet Blockers?. Circulation, 2001, 104, 2759-2761.	1.6	17
329	Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. Journal of Thrombosis and Thrombolysis, 2012, 34, 229-234.	2.1	16
330	Cardiovascular and renal benefits of dapagliflozin in patients with short and longâ€standing type 2 diabetes: Analysis from the DECLAREâ€TIMI 58 trial. Diabetes, Obesity and Metabolism, 2020, 22, 1122-1131.	4.4	16
331	Prognostic Implications of Low Level Cardiac Troponin Elevation Using Highâ€Sensitivity Cardiac Troponin T. Clinical Cardiology, 2015, 38, 230-235.	1.8	15
332	Oral dual antiplatelet therapy: what have we learnt from recent trials?. European Heart Journal, 2015, 37, ehv377.	2.2	15
333	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€"Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal, 2018, 202, 39-48.	2.7	15
334	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	6.3	15
335	Approach to the Patient with Chest Pain. , 2012, , 1076-1086.		15
336	Novel antiplatelet strategies in acute coronary syndromes. Cleveland Clinic Journal of Medicine, 2009, 76, S8-S15.	1.3	15
337	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 762-770.	0.8	14
338	Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. Chronobiology International, 2012, 29, 1390-1396.	2.0	14
339	On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 182 T 694-698.	1.6	14
340	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay inÂStable Patients With Ischemic Heart Disease. Journal of the American College of Cardiology, 2016, 68, 322-323.	2.8	14
341	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	3.9	14
342	Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. Circulation, 2021, 144, 1732-1734.	1.6	14

#	Article	IF	Citations
343	Something old, something new: Î² blockers and clopidogrel in acute myocardial infarction. Lancet, The, 2005, 366, 1587-1589.	13.7	13
344	Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 555-559.	2.0	13
345	Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsã€€â€• A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial â€•. Circulation Journal, 2021, 85, 2063-2070.	1.6	13
346	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
347	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	1.6	13
348	Fibrillary/Immunotactoid Glomerulopathy With Cardiac Involvement. Circulation, 2002, 105, e120-1.	1.6	12
349	Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. Journal of Thrombosis and Thrombolysis, 2012, 34, 222-228.	2.1	12
350	The Incidence of Kidney Injury for Patients Treated With a Highâ€Potency Versus Moderateâ€Potency Statin Regimen After an Acute Coronary Syndrome. Journal of the American Heart Association, 2014, 3, e000784.	3.7	12
351	Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction. JAMA - Journal of the American Medical Association, 2016, 315, 2525.	7.4	12
352	Response by Bonaca and Sabatine to Letters Regarding Article, â€œLow-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	12
353	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	6.1	12
354	Advances in the treatment of dyslipidemia. Cleveland Clinic Journal of Medicine, 2016, 83, 181-186.	1.3	12
355	Time for contrast material to traverse the epicardial artery and the myocardium in ST-Segment elevation acute myocardial infarction versus unstable angina pectoris/nonâ€“ST-elevation acute myocardial infarction. American Journal of Cardiology, 2003, 91, 1163-1167.	1.6	11
356	Hemodynamic Significance of Periprocedural Myocardial Injury Assessed With N-Terminal Pro-B-Type Natriuretic Peptide After Percutaneous Coronary Intervention in Patients With Stable and Unstable Coronary Artery Disease (from the JUMBO-TIMI 26 Trial). American Journal of Cardiology, 2007, 99, 344-348.	1.6	11
357	Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapyâ€“Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. American Heart Journal, 2008, 155, 133-139.	2.7	11
358	Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: Analysis from CLopidogrel as Adjunctive Reperfuslon TherapY (CLARITY) - Thrombolysis in Myocardial Infarction (TIMI) 28. American Heart Journal, 2010, 159, 964-971.e1.	2.7	11
359	<emph type="ital">CYP2C19</emph> Genotype and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2012, 307, 1482.	7.4	11
360	Biomarker of Collagen Turnover (Câ€Terminal Telopeptide) andÂPrognosis in Patients With Nonâ€STâ€Elevation Acute CoronaryÂSyndromes. Journal of the American Heart Association, 2019, 8, e011444.	3.7	11

#	Article	IF	Citations
361	Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	11
362	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	3.1	11
363	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. Diabetes, 2019, 68, 244-OR.	0.6	11
364	Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients â€“ A report from the National Cardiovascular Data Registry. American Heart Journal, 2013, 166, 1043-1049.e1.	2.7	10
365	Diagnostic Performance of Copeptin in Patients With Acute Nontraumatic Chest Pain: <scp>BWHâ€TIMI ED</scp> Chest Pain Study. Clinical Cardiology, 2014, 37, 227-232.	1.8	10
366	Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. JAMA Cardiology, 2016, 1, 627.	6.1	10
367	Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 423-432.	2.0	10
368	Efficacy of Dapagliflozin in Black Versus White Patients With HeartÂFailure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.	4.1	10
369	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	8.6	10
370	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011382.	3.9	10
371	Relationship of Dapagliflozin WithÂSerumÂSodium. JACC: Heart Failure, 2022, 10, 306-318.	4.1	10
372	Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. Journal of Thrombosis and Thrombolysis, 2000, 10, 189-196.	2.1	9
373	Prognostic Utility of Secretory Phospholipase A2 in Patients with Stable Coronary Artery Disease. Clinical Chemistry, 2011, 57, 1311-1317.	3.2	9
374	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. Journal of Thrombosis and Thrombolysis, 2021, 51, 675-681.	2.1	9
375	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 2015, 66, B36.	2.8	8
376	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUSâ€“TIMI 54. Journal of the American Heart Association, 2018, 7, e009260.	3.7	8
377	Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. European Heart Journal Digital Health, 2022, 3, 38-48.	1.7	8
378	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. European Heart Journal, 2007, 28, 2070-2076.	2.2	7

#	Article	IF	Citations
379	Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. Journal of Thrombosis and Thrombolysis, 2011, 31, 493-500.	2.1	7
380	Activated Clotting Time to Guide Heparin Dosing in Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. Circulation: Cardiovascular Interventions, 2018, 11, e006084.	3.9	7
381	Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease. Circulation, 2019, 140, 2044-2046.	1.6	7
382	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e009759.	3.9	7
383	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2Â°Pâ€TIMI 50. Journal of the American Heart Association, 2021, 10, e018673.	3.7	7
384	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation, 2021, 144, 249-251.	1.6	7
385	Longâ€Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7
386	Increases in Myocardial Workload Induced by Rapid Atrial Pacing Trigger Alterations in Global Metabolism. PLoS ONE, 2014, 9, e99058.	2.5	7
387	Effects of Dapagliflozin According to the HeartÂFailure Collaboratory Medical Therapy Score. JACC: Heart Failure, 2022, 10, 543-555.	4.1	7
388	Clopidogrel use in coronary artery disease. Expert Review of Cardiovascular Therapy, 2006, 4, 7-15.	1.5	6
389	Relation of Hyperemic Epicardial Flow to Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy. American Journal of Cardiology, 2008, 101, 1232-1238.	1.6	6
390	Cost-Effectiveness Analysis of Short-Term Clopidogrel Therapy for ST Elevation Myocardial Infarction. Critical Pathways in Cardiology, 2010, 9, 14-18.	0.5	6
391	Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. American Heart Journal, 2010, 159, 55-62.	2.7	6
392	PCSK9 inhibitors: what we know, what we should have understood, and what is to come. European Heart Journal, 2022, 43, e29-e31.	2.2	6
393	SGLT-2 inhibitors for people with type 2 diabetes â€“ Authors' reply. Lancet, The, 2019, 394, 560-561.	13.7	6
394	Response by Kato et al to Letter Regarding Article, â€œEffect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitusâ€. Circulation, 2019, 140, e740-e741.	1.6	6
395	Response by Zelniker et al to Letter Regarding Article, â€œEffect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trialâ€. Circulation, 2020, 142, e129-e130.	1.6	6
396	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	3.6	6

#	Article	IF	Citations
397	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3005-3014.	2.4	6
398	Platelets and atherothrombosis: An essential role for inflammation in vascular disease â€" A review. International Journal of Angiology, 2005, 14, 211-217.	0.6	5
399	Clopidogrel Dosing Based on Genotypeâ€"Reply. JAMA - Journal of the American Medical Association, 2012, 307, .	7.4	5
400	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC: Cardiovascular Interventions, 2020, 13, 1012-1014.	2.9	5
401	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiology, 2021, 6, 582.	6.1	5
402	Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Archives of Cardiovascular Diseases, 2021, 114, 187-196.	1.6	5
403	Differentiating Type 1 and Type 2 Myocardial Infarction. JAMA Cardiology, 2021, 6, 781.	6.1	5
404	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction â€" findings from the LATITUDEâ€"TIMI 60 trial. American Heart Journal, 2022, 243, 147-157.	2.7	5
405	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk inÂDAPA-HF. JACC: Heart Failure, 2022, 10, 104-118.	4.1	5
406	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS ONE, 2022, 17, e0266615.	2.5	5
407	Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. American Journal of Cardiology, 2005, 95, 228-233.	1.6	4
408	When prognosis precedes diagnosis: putting the cart before the horse. Cmaj, 2005, 172, 1697-1698.	2.0	4
409	Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30Âdays. Journal of Thrombosis and Thrombolysis, 2008, 26, 106-112.	2.1	4
410	Carriage of Reduced-Function CYP2C19 Allele Among Patients Treated With Clopidogrelâ€"Reply. JAMA - Journal of the American Medical Association, 2011, 305, 467.	7.4	4
411	Clinical Implications and Correlates of Q Waves in Patients With <scp>ST</scp>â€Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the <scp>CLARITYâ€TIMI</scp> 28 Trial. Clinical Cardiology, 2014, 37, 160-166.	1.8	4
412	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. Postgraduate Medicine, 2016, 128, 31-39.	2.0	4
413	The Prospects for Cardiovascular Proteomics. JAMA Cardiology, 2016, 1, 245.	6.1	4
414	PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicityâ€"Reply. JAMA Cardiology, 2017, 2, 1169.	6.1	4

#	Article	IF	Citations
415	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Journal of Clinical Lipidology, 2022, 16, 538-543.	1.5	4
416	Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 751-761.	1.4	3
417	Clopidogrel in ST-elevation myocardial infarction. Country Review Ukraine, 2006, 8, G31-G34.	0.8	3
418	Ticagrelor for acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2013, 11, 1473-1484.	1.5	3
419	Pharmacogenomics of antiplatelet drugs. Hematology American Society of Hematology Education Program, 2014, 2014, 343-347.	2.5	3
420	How We Evaluate Biomarker Studies. JAMA Cardiology, 2017, 2, 524.	6.1	3
421	Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 736-745.	1.0	3
422	Appropriate invasive and conservative treatment approaches for patients with ST-Elevation MI. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 3-11.	0.9	2
423	New Antibody Assays for Cardiovascular Disease: Future Tools for the Clinical Chemist?. Clinical Chemistry, 2009, 55, 404-406.	3.2	2
424	A Rare Complication of Infective Endocarditis. Circulation, 2012, 125, 1316-1317.	1.6	2
425	Reply. Journal of the American College of Cardiology, 2014, 63, 943.	2.8	2
426	SAFETY OF VERY LOW LDL-C LEVELS WITH EVOLOCUMAB: AN ANALYSIS OF 5942 PATIENTS FROM PHASE 2 AND 3 AND OPEN-LABEL EXTENSION STUDIES. Journal of the American College of Cardiology, 2016, 67, 1868.	2.8	2
427	Nurturing Natureâ€"Exploring the Possible Role of Epigenetics in Dyslipidemia. JAMA Cardiology, 2016, 1, 36.	6.1	2
428	Pharmacogenetics and the Promise of Personalized Medicine. JAMA Cardiology, 2018, 3, 408.	6.1	2
429	Clinical benefits of evolocumab appear less than hoped â€“ Authors' reply. Lancet, The, 2018, 391, 934-935.	13.7	2
430	DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL. Journal of the American College of Cardiology, 2019, 73, 1.	2.8	2
431	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	1.5	2
432	Moving toward Personalized Medicine. , 0, , 205-227.		1

#	Article	IF	Citations
433	Randomized, Controlled Trials. Circulation, 2011, 124, e832-4.	1.6	1
434	Editorial on PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 217-219.	3.0	1
435	Questioning the safety and benefits of evolocumab â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 11-12.	11.4	1
436	Reply. Journal of the American College of Cardiology, 2018, 71, 108.	2.8	1
437	EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction. Lancet Diabetes and Endocrinology,the, 2020, 8, 932-933.	11.4	1
438	Response by Marston et al to Letter Regarding Article, â€œThe Effect of PCSK9 (Proprotein Convertase) Tj ETQq0 0 0 rgBT /Overlock 10 e264.	1.6	1
439	Aspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting. European Heart Journal, 2021, 42, 320-322.	2.2	1
440	Letter to the editor re: â€˜serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic reviewâ€™. Expert Review of Clinical Pharmacology, 2021, 14, 281-282.	3.1	1
441	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. Circulation, 2020, 142, .	1.6	1
442	Antiplatelet Therapy in ST-Elevation Myocardial Infarction. , 0, , 164-177.		0
443	Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease. Circulation, 2011, , 1.	1.6	0
444	PROGNOSTIC PERFORMANCE OF SERIAL HIGH SENSITIVITY CARDIAC TROPONIN DETERMINATION IN STABLE ISCHEMIC HEART DISEASE: ANALYSIS FROM PROVE IT-TIMI 22. Journal of the American College of Cardiology, 2013, 61, E1147.	2.8	0
445	Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Riskâ€”Reply. JAMA - Journal of the American Medical Association, 2017, 317, 440.	7.4	0
446	Response by Watts et al to Letter Regarding Article, â€œFactorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolismâ€• Circulation, 2017, 136, 120-121.	1.6	0
447	Genomics-Guided Antithrombotic Therapy for Acute Coronary Syndromes. , 2018, , 147-161.		0
448	PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK. Journal of the American College of Cardiology, 2019, 73, 2023.	2.8	0
449	Correctly understanding the diabetes data in FOURIER. Diabetes, Obesity and Metabolism, 2019, 21, 2342-2343.	4.4	0
450	TRS2P PREDICTS MORTALITY AFTER MI IN YOUNG ADULTS: FROM THE PARTNERS YOUNG-MI REGISTRY. Journal of the American College of Cardiology, 2019, 73, 62.	2.8	0

#	Article	IF	Citations
451	Interindividual and Intraindividual Responses to PCSK9 Inhibitionâ€"Reply. JAMA Cardiology, 2019, 4, 600.	6.1	0
452	RS13. Risk of Major Adverse Limb Events and Benefits of Evolocumab in Patients With Peripheral Artery Disease by History of Prior Peripheral Revascularization. Journal of Vascular Surgery, 2019, 69, e195.	1.1	0
453	Association of APOE genotype and lipid lowering with cognitive function in a randomized placeboâ€controlled trial of Evolocumab. Alzheimer's and Dementia, 2020, 16, e047188.	0.8	0
454	PCSK9 Inhibitionâ€"A Tale of 2 Potential Treatment Opportunitiesâ€"Reply. JAMA Cardiology, 2021, 6, 481.	6.1	0
455	Myocardial Infarction and Evolocumabâ€"Reply. JAMA Cardiology, 2021, 6, 1222.	6.1	0
456	Assessment of the Change of a Continuous Variable as a Function of its Initial Valueâ€"Reply. JAMA Cardiology, 2021, 6, 1342.	6.1	0
457	Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. , 2010, , 219-233.		0
458	Clopidogrel and Salicylates. , 2011, , 139-153.		0
459	Risk Stratification in Unstable Angina and Nonâ€"ST-Segment Elevation Myocardial Infarction. , 2011, , 181-193.		0
460	236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial. Diabetes, 2019, 68, 236-OR.	0.6	0
461	Acute Coronary Syndrome. , 2021, , 59-80.		0